Valneva (VALN)

Executive Summary

Valneva is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with high unmet medical need. The company has successfully commercialized three vaccines, including Ixchiq, the world's first chikungunya vaccine approved in the US and Europe. Valneva's pipeline is anchored by late-stage candidates targeting Lyme disease (VLA15, partnered with Pfizer), shigellosis (Shigella vaccine), and Zika. The Lyme vaccine is the most advanced, currently in Phase 3 trials, and represents a significant commercial opportunity given the large and growing patient population in endemic regions. Additionally, Valneva's proprietary manufacturing platform and established commercial infrastructure position it well to capture market share in the vaccine space. Financially, the company generates revenue from its marketed products and partnership milestones, though it remains unprofitable as it invests heavily in R&D. The stock trades on the NASDAQ and Euronext, with a market cap of ~$530 million, reflecting cautious investor sentiment but significant upside potential pending pipeline catalysts.

Upcoming Catalysts (preview)

• H2 2026Lyme disease vaccine VLA15 Phase 3 data readout (VALOR trial)70% success
• Q2 2026Chikungunya vaccine Ixchiq sales beat and label expansion for pediatric population60% success
• H1 2026Shigella vaccine Phase 2 efficacy data50% success